Bioanalysis is determining the concentration of drugs and metabolites
in biological fluids (i.e. plasma and urine). During the past 15 years
tremendous advances in bioanalysis, for example HPLC, auto injectors,
data collection systems and robotics has enabled the productivity of
the bioanalyst to increase but it still requires considerable manual i
ntervention. This paper describes the rationale, the justification and
the plans Bristol-Myers Squibb has to completely automate the entire
bioanalytical process.